FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental oncology, and can be used for inducing an abscopal anti-tumor effect in an experimental Ehrlich's carcinoma model. It is followed by subcutaneous bilateral transplantation of ascitic Ehrlich's carcinoma in mice, formation of tumor contralateral nodes on lower extremities and subsequent local irradiation of one of tumor nodes. In 5 days after single-stage bilateral transplantation of tumor and formation of tumor nodes from both sides, local single irradiation of one of tumor nodes is performed 60Co γ-beams in dose of 30 Gy, without preliminary stimulation of animals immunity.
EFFECT: method provides creating an experimental model for implementing an abscopal effect on a distant tumor without using additional inductors by selecting optimal doses and modes of radiation therapy, which leads to systemic activation of immune-mediated anti-tumor response, including to distant metastatic tumor centers.
1 cl, 2 dwg, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PROTON THERAPY FOR SOLID EHRLICH CARCINOMA | 2023 |
|
RU2808984C1 |
COMPLEX ANTI-TUMORAL PRODUCT | 2020 |
|
RU2751776C2 |
METHOD OF INCREASING THE EFFICIENCY OF PROTON THERAPY ON MELANOMA STEM CELLS | 2022 |
|
RU2798733C2 |
METHOD OF COMBINED RADIOTHERAPY AND PHOTODYNAMIC THERAPY | 2019 |
|
RU2724480C2 |
METHOD OF INCREASING ANTI-TUMOUR RESISTANCE | 2009 |
|
RU2418599C1 |
INDOL-3-CARBOXIC ACID DERIVATIVES WITH ANTI-TUMOR ACTIVITY | 2022 |
|
RU2782931C2 |
AGENT FOR TARGETED THERAPY OF MALIGNANT GROWTHS | 2018 |
|
RU2699558C2 |
METHOD FOR PROTON-RESISTANT TUMOR CELL CULTURE | 2018 |
|
RU2691853C2 |
ANTI-TUMOR AGENT BENZAMIDE | 2003 |
|
RU2257894C1 |
METHOD OF INHIBITING RADIATION-INDUCED INCREASE IN HUMAN BREAST CANCER STEM CELLS | 2022 |
|
RU2800366C2 |
Authors
Dates
2020-11-11—Published
2020-05-07—Filed